Article Text

This article has a correction. Please see:

Download PDFPDF
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe
  1. P Emery1,
  2. R Van Vollenhoven2,
  3. M Ostergaard3,
  4. E Choy4,
  5. B Combe5,
  6. W Graninger6,
  7. K Krueger7,
  8. M Matucci-Cerinic8,
  9. F Navarro9,
  10. P van Riel10,
  11. L Settas11,
  12. S Steinfeld12
  1. 1
    University of Leeds, Leeds, UK
  2. 2
    Karolinska University Hospital, Stockholm, Sweden
  3. 3
    Hvidovre University Hospital, Copenhagen, Denmark
  4. 4
    King’s College, London, UK
  5. 5
    Hopital Lapeyronie, Montpellier, France
  6. 6
    University of Graz, Graz, Austria
  7. 7
    University of Munich, Munich, Germany
  8. 8
    University of Florence, Florence, Italy
  9. 9
    Hospital General Universitatrio Virgen Macarena, Seville, Spain
  10. 10
    Radboud University Nijmegen, Nijmegen, The Netherlands
  11. 11
    University of Thessaloniki, Thessaloniki, Greece
  12. 12
    Erasme University Hospital, Brussels, Belgium
  1. Professor P Emery, Leeds Teaching Hospitals NHS Trust, Academic Section of Musculoskeletal Disease, 2nd Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK; p.emery{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease. In the majority of patients the course is progressive and leads to destruction of joints, functional disability, reduced quality of life and increased morbidity and mortality. Advances in treatment for RA have been associated with an improvement in the health status of patients with RA in recent years.1 While the management of RA varies widely across Europe,2 the underlying pathophysiology does not differ between countries. A cross-sectional comparison of patients with RA in 15 different countries (largely European) revealed great variation in the drug management of patients with RA, including the delay in starting a disease-modifying antirheumatic drug (DMARD) ranging from <6 to >12 months, use of methotrexate (<80% of patients in the UK and Serbia had received methotrexate) and use of biological agents (>40% in France and Ireland vs. <10% in Serbia and Poland).3 It is also noteworthy that disease activity scores varied and were highest, on average, in Serbia and Poland.3

Although tumour necrosis factor (TNF) inhibitors have undoubtedly significantly advanced the treatment of RA, they are a higher cost treatment option and may not be suitable for all patients.4 Hence, guidelines have been developed in order to assist the appropriate use of TNF inhibitors within individual countries.

In order to establish the level of access to TNF inhibitors across Europe, European guidelines were translated and reviewed with regard to their similarities and differences in the recommended criteria for the initiation of TNF inhibition. Particular attention was paid to recommended duration of disease and prior treatment with DMARDs, as well as disease activity levels.

The guidelines selected for inclusion were those from Belgium,5 Czech Republic,6 Denmark,7 France,8 9 Germany,10 Italy,11 Romania,12 Spain,13 Sweden14 and the …

View Full Text


  • Competing interests: RVV has received consulting honoraria and speaker’s fees from Wyeth. EC has served on advisory boards and speaker bureaus for Abbott, Schering Plough, Wyeth, UCB Celltech and Roche. WG has served on an advisory board and Speaker Bureaus for Abbott, Schering Plough, Wyeth, UCB Celltech and Roche. SS has served in advisory boards for Abbott, Schering-Plough, Genentech and Wyeth. BC has served as a speaker and/or consultant and/or investigator for Abbott, BMS, GSK, MSD, Roche, Schering, UCB and Wyeth. PE has provided expert advice and undertaken clinical trials for Abbott, BMS, GSK, MSD, Roche, Schering, UCB and Wyeth.

  • Funding: Wyeth provided an unrestricted grant for research and writing of this article.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism